ArticleInternational journal of molecular sciences2020
Antibiotics Act with vB_AbaP_AGC01 Phage against
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2025Pooled it
- Model-dependent efficacy of sequential phage-antibiotic-antifungal therapy against dual-species biofilms.Biofilm · 2026Article
- Extensive screening of ten bacteriophage cocktails revealed an optimal combination with potent therapeutic activity against Acinetobacter baumannii.Scientific reports · 2026Article
- Genomic characterization of Pseudomonas aeruginosa infecting Abidjanvirus Lucjan.Molecular genetics and genomics : MGG · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation and characterization of a novel phage AbT1 and evaluating its anti-biofilm activity and antibiotic synergy.Molecular biology reports · 2026Article
- Advances in phage therapy forFrontiers in microbiology · 2026Review
- In Vitro Antibacterial Efficacy of Recombinant Phage-Derived Endolysin LysTAC1 Against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Isolation and identification of a newly discovered broad-spectrum Acinetobacter baumannii phage and therapeutic validation against pan-resistant Acinetobacter baumannii.Virologica Sinica · 2025Article
- Bacteriophage Indie resensitizes multidrug-resistant Acinetobacter baumannii to antibiotics in vitro.Scientific reports · 2025Article
- Synergistic antibacterial activity of curcumin and phage against multidrug-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Isolation, characterization and therapeutic evaluation of phage HHU1 against K2Frontiers in cellular and infection microbiology · 2025Article
- Phage-antibiotic combinations againstFrontiers in microbiology · 2025Article
- Identification of multi-drug resistantFrontiers in microbiology · 2025Article
- A review of the fighting Acinetobacter baumannii on three fronts: antibiotics, phages, and nanoparticles.Molecular biology reports · 2024Review
- Synergistic Antimicrobial Effects of Phage vB_AbaSi_W9 and Antibiotics againstAntibiotics (Basel, Switzerland) · 2024Article
- Lytic Capsule-SpecificViruses · 2024Article
- Resistance to bacteriophage incurs a cost to virulence in drug-resistantJournal of medical microbiology · 2024Article
- Characterization of bacteriophage vB_AbaS_SA1 and its synergistic effects with antibiotics against clinical multidrug-resistant Acinetobacter baumannii isolates.Pathogens and disease · 2024Article
- Long-Term Effectiveness of Engineered T7 Phages Armed with Silver Nanoparticles AgainstInternational journal of nanomedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Increasing multidrug resistance has led to renewed interest in phage-based therapy. A combination of the bacteriophages and antibiotics presents a promising approach enhancing the phage therapy effectiveness. First, phage candidates for therapy should be deeply characterized. Here we characterize the bacteriophage vB_AbaP_AGC01 that poses antibacterial activity against clinical Acinetobacter baumannii strains. Moreover, besides genomic and phenotypic analysis our study aims to analyze phage-antibiotic combination effectiveness with the use of ex vivo and in vivo models. The phage AGC01 efficiently adsorbs to A. baumannii cells and possesses a bacteriolytic lifecycle resulting in high production of progeny phages (317 ± 20 PFU × cell
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.